Merck Vaccine Shown to Prevent Cervical Cancer Linked to HPV

Drug Industry Daily
KEYWORDS Markets / NDA
A A

In a late-stage clinical trial, a Merck vaccine that targets the human papilloma virus (HPV) prevented virtually 100 percent of growths that can lead to cervical cancer, the company said Oct. 6.

To View This Article:

Login

Subscribe To Drug Industry Daily